Requesting your support

Supporting cancer clinical trial research in Canada

Most cancer treatments used today were first proven effective through high-quality cancer clinical trials like those led by the Canadian Cancer Trials Group (CCTG). CCTG is a collaborative network of dedicated researchers, physicians, scientists and statisticians globally recognized for finding treatments that give people with cancer longer, better quality lives.

Created in 1980, CCTG is the largest cancer research network in Canada with over 5200 active members and 2100 investigators. The group has also created an important international network with trials in over 40 countries.

CCTG-led trials have resulted in major, life-saving breakthroughs in breast, colorectal, blood, lung, ovarian, brain and prostate cancer. Right now CCTG is leading a non-small cell lung cancer trial in a dozen countries looking to cure the leading cancer killer in North America. In 2016, CCTG was recognized by the American Society of Clinical Oncology for leading two of the four most important cancer trials in the world – an unprecedented feat for any cancer clinical trials group.

CCTG is the most significant cancer research investment in Canada in terms of direct impact on patients.

However, despite this record of excellence and the countless number of lives saved, CCTG does not have stable funding and has to rely on grants, that are never assured, to continue their work. This means that many necessary trials are on hold or are taking longer to complete.

For example, the Challenge Trial, an international trial expected to improve colon cancer survival rates, is showing great promise but requires funding to test the impact of an exercise treatment on colon cancer survivors. The lack of stable support has slowed trial progress meaning that a potential new treatment has been delayed.

As our understanding of cancer grows, we rely on CCTG to safely conduct clinical trials based on new discoveries. While other organizations support CCTG, it is not enough for the number of trials that are needed. The cure for cancer will come from clinical trials. Your gift will enable CCTG researchers to safely conduct the growing number of trials needed to improve the lives of cancer patients across Canada and the world.

To support any of CCTG's high impact initiatives contact: William Leacy or visit the CCTG donatioon page to donate online

 

The development of a cancer clinical trial - Your support is what makes the difference!

 

Janet Dancey, Director of CCTG

Canadian Cancer Trials Group awarded $25 million in funding to support clinical trials

The Canadian Cancer Trials Group (CCTG) has been awarded more than 19 million USD over six years (approximately $25 million CAD) from the U.S. National Institutes of Health (NIH) and National Cancer Institute (NCI).

More >>
 

Strength in Numbers

Patients facing a cancer diagnosis invariably have many questions, but one tops the list – what is the best treatment? Answering that question is the compelling goal of medical research that is testing new treatments for similarly-diagnosed patients in carefully monitored and controlled ways.

More >>
 
New Investigator Cancer Trials Practicum 2019 - 2020

New Investigator Cancer Trials Practicum 2019 - 2020

The Canadian Cancer Trials Group (CCTG) is very excited to announce that the the 2019-2020 New Investigator Cancer Trials Practicum applications are open. This is a unique opportunity for new investigators to access hands on training and practical work in the field of cancer clinical trials. The purpose of the CCTG New-Investigator Cancer Trials Practicum is to deliver a training program that includes practical trial experience at cancer sites across the country over a one-year period.

More >>
 
Precision medicine targeting each individuals unique form of cancer

The rise of precision medicine

Today we think about cancer in terms of the tumour site—breast, lung, colon, brain, each is separate with different treatments. Precision medicine is a new way of looking at cancer. Instead of focusing on the site of the cancer, it identifies the genetic abnormalities that make cancer possible in individual patients.  

More >>